Literature DB >> 11724255

Non-contrast enhanced MR venography using 3D fresh blood imaging (FBI): initial experience.

K Yokoyama1, T Nitatori, S Inaoka, T Takahara, J Hachiya.   

Abstract

OBJECTIVE: This study examined the efficacy of 3D-fresh blood imaging (FBI) in patients with venous disease in the iliac region to lower extremity.
MATERIALS AND METHODS: Fourteen patients with venous disease were examined [8 deep venous thrombosis (DVT) and 6 varix] by 3D-FBI and 2D-TOF MRA. All FBI images and 2D-TOF images were evaluated in terms of visualization of the disease and compared with conventional X-ray venography (CV).
RESULTS: The total scan time of 3D-FBI ranged from 3 min 24 sec to 4 min 52 sec. 3D-FBI was positive in all 23 anatomical levels in which DVT was diagnosed by CV (100% sensitivity) as well as 2D-TOF. The delineation of collateral veins was superior or equal to that of 2D-TOF. 3D-FBI allowed depiction of varices in five of six cases; however, in one case, the evaluation was limited because the separation of arteries from veins was difficult.
CONCLUSION: The 3D-FBI technique, which allows iliac to peripheral MR venography without contrast medium within a short acquisition time, is considered clinically useful.

Entities:  

Mesh:

Year:  2001        PMID: 11724255

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  3 in total

1.  Interactive two-dimensional fresh blood imaging: a feasibility study.

Authors:  Pauline Wong; Martin J Graves; David J Lomas
Journal:  Eur Radiol       Date:  2008-11-04       Impact factor: 5.315

2.  Repeatability of Non-Contrast-Enhanced Lower-Extremity Angiography Using the Flow-Spoiled Fresh Blood Imaging.

Authors:  Yuyang Zhang; Zhen Xing; Dejun She; Nan Huang; Dairong Cao
Journal:  J Comput Assist Tomogr       Date:  2018 Jan/Feb       Impact factor: 1.826

3.  Usefulness of non-contrast-enhanced magnetic resonance imaging prior to venous interventions.

Authors:  Agnieszka Kusiak; Jacek Budzyński
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-09-18       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.